IP Verse

Il-2Rbeta-Selective Agonists In Combination With An Anti-Ctla-4 Antibody Or An An Anti-Pd-1 Antibody - EP3134123

The patent EP3134123 was granted to Nektar Therapeutics on Feb 17, 2021. The application was originally filed on Feb 20, 2015 under application number EP15721044A. The patent is currently recorded with a legal status of "Revoked".

EP3134123

NEKTAR THERAPEUTICS
Application Number
EP15721044A
Filing Date
Feb 20, 2015
Status
Revoked
Mar 8, 2024
Grant Date
Feb 17, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GREINERNov 17, 2021GREINER -

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2006138572
DESCRIPTIONWO2012065085
DESCRIPTIONWO2012065086
INTERNATIONAL-SEARCH-REPORTWO2006121168
INTERNATIONAL-SEARCH-REPORTWO2012065086
OPPOSITIONIN2014DEL3087
OPPOSITIONIN2014DEL499
OPPOSITIONWO2006121168
OPPOSITIONWO2012065086
OPPOSITIONWO2015125159

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Ajay V. Maker ; Giao Q. Phan ; Peter Attia ; James C. Yang ; Richard M. Sherry ; Suzanne L. Topalian ; Udai S. Kammula ; Richard E. Royal ; Leah R. Haworth ; Catherine Levy ; David Kleiner ; Sharon A. Mavroukakis ; Michael Yellin ; Steven A. Rosenberg, "Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study", Annals of Surgical Oncology, Springer-Verlag, Ne, Ne , (20051201), vol. 12, no. 12, ISSN 1534-4681, pages 1005 - 1016, XP019369612-
OPPOSITION- Amin A., White R. J., "High-Dose lnterleukin-2: Is It Still Indicatedfor Melanoma and RCC in an Era of Targeted Therapies?", ONCOLOGY, (20130715), vol. 27, no. 7, pages 1 - 47, XP055870511-
OPPOSITION- Anonymous, "History of Changes for Study: NCT01358721 Phase I Biomarker Study (BMS-936558) ", clinical study NCT01358721, (20140117), pages 1 - 10, clinical study NCT01358721, URL: https://www.clinicaltrials.gov/ct2/history/NCT01358721 ?V_40=View#StudyPageTop, (20211208), XP055870582-
OPPOSITION- Anonymous, "History of Changes for Study: NCT01629758 Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors ", clinical study NCT01629758, (20131009), pages 1 - 18, clinical study NCT01629758, URL: https://clinicaltrials.gov/ct2/history/NCT01629758?V 11 =View#StudvPaqeTop, (20211208), XP055870577-
OPPOSITION- Anonymous, "Interleukin 2", WIKIPEDIA, (20140122), pages 1 - 3, WIKIPEDIA, URL: https://en.wikipedia.Org/w/index.php?title=lnterleukin_2&oldid=591813038, (20211208), XP055870590-
OPPOSITION- Charych D. H., Addelpalli M., Lee S., Chang T., Liu X., Pena R., "An engineered immunotherapy (NKTR-214) with altered selectivity toward the IL2 receptor : Efficacy and tolerability in a murine tumor model", Journal of Clinical Oncology, (20130101), vol. 31, no. 15, pages 1 - 3, XP055870532-
OPPOSITION- CHARYCH, D. H. et al., "An engineered immunotherapy (NKTR-214) with altered selectivity towards the IL-2 receptor : Efficacy and tolerability in a murine tumor model", Poster, pages 1 - 1-
OPPOSITION- West E., Ha S. J., Tan W., Jin H. T., Freeman G., Smith K., Ahmed R., "IL-2 therapy synergizes with PD-L1 blockade to rescue exhausted CD8+ T cells during chronicviral infection (137.24)", The Journal of Immunology, (20100101), vol. 184, no. 1, pages 1 - 3, XP055870539-
OPPOSITION- Hamid Omid; Carvajal Richard D, "Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy", Expert opinion on biological therapy, Informa Healthcare, UK, UK , (20130601), vol. 13, no. 6, doi:10.1517/14712598.2013.770836, ISSN 1744-7682, pages 847 - 861, XP008170016
OPPOSITION- David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), vol. 2, no. 5, doi:10.1002/cam4.106, ISSN 20457634, pages 662 - 673, XP055157252
OPPOSITION- Wei Liao, Jian-Xin Lin, Warren j. Leonard, "Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20130101), vol. 38, no. 1, doi:10.1016/j.immuni.2013.01.004, ISSN 1074-7613, pages 13 - 25, XP055225914
OPPOSITION- Kathrin Schwager, Teresa Hemmerle, David Aebischer, Dario Neri, "The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF", Journal of Investigative Dermatology, Elsevier, NL, NL , (20130301), vol. 133, no. 3, doi:10.1038/jid.2012.376, ISSN 0022-202X, pages 751 - 758, XP055289350
OPPOSITION- Brayer Jason; Fishman Mayer, "Regression of Metastatic Clear Cell Kidney Cancer With Interleukin-2 Treatment Following Nivolumab (Anti-PD-1) Treatment", Journal of Immunotherapy, Lippincott Williams & Wilkins, US, US , (20140331), vol. 37, no. 3, doi:10.1097/CJI.0000000000000024, ISSN 1524-9557, pages 187 - 191, XP009510180
OPPOSITION- P. A. Prieto, J. C. Yang, R. M. Sherry, M. S. Hughes, U. S. Kammula, D. E. White, C. L. Levy, S. A. Rosenberg, G. Q. Phan, "CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma", Clinical Cancer Research, Association for Cancer Research, (20120401), vol. 18, no. 7, doi:10.1158/1078-0432.CCR-11-1823, ISSN 10780432, pages 2039 - 2047, XP055071153
OPPOSITION- Erin E. West, Hyun-Tak Jin, Ata-Ur Rasheed, Pablo Penaloza-Macmaster, Sang-Jun Ha, Wendy G. Tan, Ben Youngblood, Gordon J. Freeman, Kendall A. Smith, Rafi Ahmed, "PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells", The Journal of Clinical Investigation, B M J Group, GB, GB , (20130603), vol. 123, no. 6, doi:10.1172/JCI67008, ISSN 0021-9738, pages 2604 - 2615, XP055404072
OPPOSITION- Joseph R Broucek;Tasha Hughes;Erica J Huelsmann;Joseph L Poshepny;Carl E Ruby;Andrew Zloza;Howard L Kaufman, "Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival", Journal for ImmunoTherapy of Cancer, BioMed Central, London, GB, GB , (20131107), vol. 1, no. 1, doi:10.1186/2051-1426-1-S1-P70, ISSN 2051-1426, page P70, XP021167283
OPPOSITION- M. K. Callahan, J. D. Wolchok, "At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy", Journal of Leukocyte Biology, John Wiley & Sons Ltd., GB, GB , (20130701), vol. 94, no. 1, doi:10.1189/jlb.1212631, ISSN 0741-5400, pages 41 - 53, XP055223891

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents